News | August 11, 2025
Emcure Pharmaceuticals reports Q1 FY26 consolidated PAT higher at Rs. 206.95 Cr
Emcure Pharmaceuticals has reported total income of Rs. 2,104.23 crores during the period ended June 30, 2025
Emcure Pharmaceuticals has reported total income of Rs. 2,104.23 crores during the period ended June 30, 2025
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Vasograin Plus represents a major advancement in the treatment of migraine
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
Torrent Pharmaceuticals has reported total income of Rs. 3,141 crores during the period ended June 30, 2025
He has previously served in pivotal HR leadership roles at RPG Life Sciences, Akumentis Healthcare, and Wockhardt
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Subscribe To Our Newsletter & Stay Updated
